NCT03476135View on ClinicalTrials.gov

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
Meningococcal Infections
Interventions
BIOLOGICAL

MenACYW conjugate vaccine

Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular

Trial Locations (8)

20520

Sanofi Pasteur Investigational Site 2460004, Turku

28100

Sanofi Pasteur Investigational Site 2460001, Pori

33100

Sanofi Pasteur Investigational Site 2460003, Tampere

90220

Sanofi Pasteur Investigational Site 2460008, Oulu

02230

Sanofi Pasteur Investigational Site 2460005, Espoo

00100

Sanofi Pasteur Investigational Site 2460006, Helsinki

00930

Sanofi Pasteur Investigational Site 2460002, Helsinki

04400

Sanofi Pasteur Investigational Site 2460007, Järvenpää

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03476135 - Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children | Biotech Hunter | Biotech Hunter